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Background: High-dose-rate (HDR) brachytherapy using the mold technique is a less invasive treatment for early
lip and oral cavity cancer. However, limited reports exist regarding the feasibility of this method. In this
retrospective study, we evaluated the outcome of this therapy and investigated its feasibility for lip and oral cavity
tumors.
Methods: Between May 2002 and December 2010, 17 patients (median age, 80.0 years) with histologically
confirmed squamous cell carcinoma of the lip or oral cavity were treated by means of HDR brachytherapy using
the mold technique after external beam radiotherapy (EBRT). Tumor sites included the buccal mucosa in eight
cases, the gingiva in three cases, the lips in two cases, the floor of the mouth in two cases, and the hard palate in
two cases. For all patients, EBRT (30 Gy/15 fractions), was performed before HDR brachytherapy. Two 6-Gy fractions
were delivered twice daily for 2 days a week with an interval of 6 hours between the fractions. The total HDR
brachytherapy dose was 24 Gy. Prior to EBRT, two patients with neck metastasis underwent neck dissection, and
one patient with an exophytic tumor underwent tumor resection.
Results: The median follow-up period was 53.4 (range, 4.8–83.4) months. Of the 17 patients, 14 (82.4%) achieved a
complete response, and three (17.6%) displayed a partial response.
The overall 3- and 5-year survival rates were both 68.8%, the 3- and 5-year disease-specific survival rates were both
86.7%, and the 3- and 5-year local control rates were both 54.1%. Seven patients developed local recurrence at a
median time of 3.4 (range, 1.7–29.1) months after treatment. Nodal and lung metastases occurred separately in two
patients. By the end of the follow-up period, two patients had died of the primary disease and four patients had
died of other causes.
Conclusions: Although there is a need to improve the technical aspects of the treatment protocol, HDR
brachytherapy using the mold technique might be a therapeutic option for superficial lip or oral cavity tumors,
especially in older patients who have a poor performance status or are in poor physical condition.
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Low-dose-rate (LDR) and high-dose-rate (HDR) brachy-
therapy are often employed for the radical treatment of
early-stage lip and oral cavity cancer, because they preserve
the shape and function of tissues and organs to a greater
degree than surgical treatment [1,2]. LDR and HDR brachy-
therapy achieve equivalent therapeutic outcomes, but LDR* Correspondence: asaumi@md.okayama-u.ac.jp
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Khalilur et al. reported that LDR brachytherapy was safe
for very elderly patients with tongue carcinoma and
achieved outcomes comparable with those seen in youn-
ger patients [3]. However, it is sometimes difficult to treat
patients who have a poor performance status or a declin-
ing physical condition with LDR brachytherapy because of
the need to isolate them.
Remote afterloading HDR brachytherapy using an Ir-192
microsource has resolved this problem, but this technique
is mainly used for interstitial irradiation of carcinomas ofral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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Unetsubo et al. Radiation Oncology  (2015) 10:81 Page 2 of 8the lip, tongue, and floor of the mouth [1,2,4-6]. Although
intracavitary irradiation is a less invasive treatment than
interstitial irradiation, it is rarely used for oral cavity can-
cers. The limited use of intracavitary irradiation is attribut-
able to the limited treatment provided for superficial oral
tumors, and the absence of oral equivalents of the off-the-
shelf applicators used to treat cancer of the uterine cervix,
such as the tandem and ovoid applicator. For superficial
oral cavity tumors, some authors (including us) have re-
ported the effectiveness of HDR brachytherapy using a
mold [7-12]. However, these previous studies only in-
cluded a few cases with short follow-up periods [7-12].
The aim of this retrospective study was to evaluate the
therapeutic outcome of this method and investigate its
feasibility for lip and oral cavity tumors.
Methods
Patients
Between May 2002 and December 2010, a total of 17 pa-
tients (10 males and 7 females) with lip or oral cavity tu-
mors were treated using mold therapy with an HDR
remote afterloading unit and an Ir-192 microsource
(microSelectron HDR: Nucletron Co., Veenendaal, The
Netherlands) at Okayama University Hospital. All tu-
mors were histologically identified as squamous cell car-
cinoma. The characteristics of the patients are shown in
Table 1. Their median age was 80 (range, 59–94) years
(mean age, 78.2 years).
Of the 17 patients, 15 had primary tumors and two
had recurrent tumors. Four, nine, and four patients dis-
played Eastern Cooperative Oncology Group perform-
ance statuses of PS0, 1, and 2, respectively. The tumor
sites were as follows: buccal mucosa, eight cases; gingiva,
three cases; lip, two cases; floor of the mouth, two cases;
and hard palate, two cases. In accordance with the 2009
Union for International Cancer Control system, the
tumor stage was T1 in one patient, T2 in 11 patients,
and T3 in five patients. Two patients had regional lymph
node metastasis (N1 and N2b), three patients with PS0
refused surgical treatment, and 14 patients could not
undergo radical surgical treatment for the primary
tumor because of their age, performance status, poor
physical condition, and/or family problems. In addition,
it was difficult for patients to undergo interstitial LDR
brachytherapy because of the need to isolate them.
When determining the indications for HDR brachyther-
apy, we expected that mold therapy could be used as a
radical treatment for cases such as some buccal mucosa
T1, hard palate and gingiva. However, we treated patients
using mold therapy as the second choice, even in cases
such as some buccal mucosas at stages >T2, and others
involving the adaptation region such as the floor of the
mouth; this was because there was no choice but to use
conventionally-fractionated external beam radiation, andwe could not choose a palliative irradiation. All patients
provided written informed consent. The research proto-
cols for this study were approved by the ethical committee
of Okayama University Graduate School of Medicine,
Dentistry, and Pharmaceutical Sciences (Number: 1860).
Radiotherapy
Two patients with lymph node metastasis underwent
upper neck dissection before starting radiotherapy. One
patient with an exophytic tumor in the buccal mucosa
underwent partial tumor resection to decrease the
thickness of the tumor prior to the commencement of
radiotherapy.
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Figure 1. In all patients, external beam radiotherapy
(EBRT) involving a radiation dose of 30 Gy (2 Gy/day,
five fractions/week) was performed with 4-MV X-rays
before HDR brachytherapy. All patients were treated
with parallel opposing lateral or anterior-posterior
fields. Before HDR brachytherapy, a mold made of
resin was prepared for each patient. Prior to embed-
ment of the catheters into the mold, the gross tumor
volume (GTV) was determined after EBRT. We de-
fined the area displaying mucositis after EBRT as the
GTV by direct inspection and using findings from
magnetic resonance imaging and/or ultrasonography
performed before EBRT. To minimize the area at risk
of complications, we used the GTV as the clinical tar-
get volume (CTV), and 5 mm was added to the CTV to
obtain the planning target volume (PTV). A median of
4 (range, 3–10) catheters were embedded in the mold
at parallel intervals of 10 mm so that they could cover
a sufficient proportion of the PTV. For six patients we
used the two-piece mold technique, which is a method
for shifting the irradiation plane by dividing the mold
for the tumors close to the commissure of the lips [12].
Because the catheter was hard and had poor flexibility,
an adequate radiation dose could not be administered
to a tumor that had extended towards the skin region
from the corner of the mouth, or near the corner of
the mouth. Indeed, it is not the way that the tumor is
irradiated from the skin side. The dose reference point
was set at 5 mm below the surface of the mucosa for
all patients. The dose distributions were calculated
using a computer software program (Plato Brachytherapy:
Nucletron Co., Veenendaal, The Netherlands). HDR
brachytherapy was performed after EBRT. The interval be-
tween EBRT and HDR brachytherapy had a median dur-
ation of 8 (range, 7–20) days. Two 6-Gy fractions were
delivered twice a day for 2 days a week with an interval of
6 hours between the fractions. The total HDR brachyther-
apy dose was 24 Gy (Figure 2).Figure 1 Radiotherapy treatment schedule. EBRT: External beam radiothOverall survival, disease-specific survival (DSS), and
local control rates were calculated from the date of the
first treatment to the events of interest. The local control
rates were determined from imaging findings, clinical
physical examinations, or pathological tissue findings. All
survival data and local control rates were estimated ac-
cording to the Kaplan-Meier method.
All symptoms were classified according to the Common
Terminology Criteria for Adverse Events version 4.0 when
applicable.
Results
Treatment was not suspended due to radiation-induced
complications or other reasons in any patient. In one pa-
tient with buccal cancer, EBRT did not result in suffi-
cient tumor shrinkage. Hence, part of the tumor was
resected to decrease its thickness before HDR brachy-
therapy was started, and the interval between EBRT and
HDR brachytherapy in this patient was 20 days.
The median total treatment period was 38 (range, 31–49)
days. The radiation source strength for each HDR
brachytherapy fraction ranged from 161.7–349.2 GBq.
All patients experienced grade 1 (nine patients) or 2
(eight patients) acute mucositis. The six patients treated
with two-piece molds suffered from grade 2 dermatitis.
After HDR brachytherapy, a complete response (CR)
was achieved in 14 patients (82.4%), and a partial re-
sponse (PR) was achieved in 3 patients (17.6%). Of the
three patients who achieved a PR, two had tumors in
the buccal mucosa and one had a tumor in the floor of
the mouth. One patient (buccal mucosa) received add-
itional HDR brachytherapy (24 Gy in 4 fractions over
2 weeks) 4 months after the initial treatment. One pa-
tient (floor of the mouth) underwent tumor resection
and remained disease-free until the end of the follow-up
period. The remaining patient (buccal mucosa) under-
went stereotactic radiotherapy (SRT) with a CyberKnife
(Accuray Inc., Sunnyvale, CA, USA) at a total dose of
35 Gy delivered in 5 fractions.erapy, HDR: High-dose-rate.
Figure 2 Dose distribution of RALS.
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months. The overall 3- and 5-year survival rates were both
68.8% (Figure 3), the 3- and 5-year DSS rates were both
86.7% (Figure 4), and the 3- and 5-year local control rates
were both 54.1% (Figure 5).
Seven patients (CR, four patients; PR, three patients)
developed local recurrence at a median time of 3.4
(range, 1.7–29.1) months after treatment. Of these seven
patients, four (CR, two patients; PR, two patients)underwent successful salvage surgery. One patient who
achieved a PR and underwent SRT died of a recurrent
tumor at 9.8 months after the initial treatment. In
addition, one of the patients who achieved a CR but
rejected additional treatment died of a recurrent tumor
at 10.0 months after treatment. The disease in the other
patient who achieved a CR was controlled with add-
itional HDR brachytherapy (24 Gy in 4 fractions over
2 weeks) at 8 months after treatment. Nodal metastases
Figure 3 Overall survival rate.
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This patient who achieved a CR underwent successful
radical neck dissection. Lung metastasis occurred in the
patient who achieved a PR and underwent SRT. In two
patients, local recurrence occurred at the PTV margin.
Both patients had tumors in the buccal mucosa. The
longest diameter of one of the tumors was 25 mm, and
that of the other was 10 mm.
At the end of the follow-up period, two patients had
died of the primary disease, and four patients had died
of other causes (two developed pneumonia, one devel-
oped oropharyngeal cancer, and one developed esopha-
geal cancer).Figure 4 Disease-specific survival rate.In terms of late complications, fistula formation be-
tween the skin and buccal mucosa (grade 3) was observed
in the patient who underwent SRT for the primary tumor.
In addition, one patient with hard palate cancer developed
ulceration (grade 3) in the palatal mucosa.
Discussion
The outcomes of LDR brachytherapy for early lip and
oral cavity cancer are reportedly equivalent to those
achieved using surgical treatment [1,2,13]. The effective-
ness of HDR interstitial brachytherapy using the plastic
tube technique for these cancers has also been estab-
lished [1,2,4,5]. Some authors (including us) have
Figure 5 Local control rate.
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mold technique for early lip and oral cavity cancer, but
these studies only involved a few cases with short
follow-up periods [7-12]. In this retrospective study, we
evaluated the outcomes of 17 patients with lip and oral
cavity cancer treated using HDR brachytherapy using
the mold technique, although it should be noted that
their primary tumor sites varied. Our overall 5-year sur-
vival rate was 68.8%, which is not satisfactory. On the
other hand, our 5-year disease-specific survival (DSS)
rate was 86.7%. We consider that the difference between
the overall survival and DSS rates was due to the high
percentage of elderly patients (median age, 80 years) in
our study. Indeed, 4 of the 17 patients (23.5%) died of
other causes. One reason for the high percentage
(70.6%) of elderly patients (aged > 75 years) in our study
was that surgical treatment and LDR brachytherapy were
avoided by the subjects, as well as by their doctors and
relatives, because of the age-related decline in their per-
formance status and physical condition. In a previous
study, Khalilur et al. [3] examined patients with tongue
cancer who had an age distribution similar to that in our
study population. Their patients were treated with LDR
brachytherapy using Au-198, and the 5-year overall sur-
vival and DSS rates were 49% and 68%, respectively [3].
Our 5-year overall survival and DSS rates were similar.
However, our 5-year local control rate (54.1%) was lower
than theirs (86%) [3]. In our study, local recurrence oc-
curred in seven patients (41.2%), including three patients
who achieved a PR. Three of the four patients who
achieved a CR developed local recurrence within
12 months of treatment; local recurrence developed after29.1 months in the remaining patient. As to the reason
for our unsatisfactory outcomes regarding PR and local
failure, we suspect that our treatment protocol might
have been inappropriate.
With regard to whether or not HDR brachytherapy
should be combined with EBRT, several authors have re-
ported HDR brachytherapy protocols involving the mold
technique for the treatment of oral cancer (Table 2)
[7-11]. In the present study, we performed EBRT to de-
crease the thickness of the tumor as much as possible
before the administration of HDR brachytherapy using
the mold technique, and determined the total radiation
dose of EBRT to be 30 Gy; this is less than the tolerated
dose (TD5/5 = 32 Gy for parotid glands) of the salivary
glands which are often included in the irradiation field.
In the oral mucosal carcinoma, the area of radiation
tumoritis, which is the early tumor reaction, was often
larger than the area occupied by the gross tumor before
EBRT. In those cases, we determined the GTV as the
area displaying mucositis (tumoritis) after irradiation to
avoid tumor recurrence in the margins.
In the present study, two patients with buccal carcin-
oma suffered local recurrence at the PTV margin. We
defined the PTV as the GTV (=CTV) + 5 mm to reduce
the area at risk of complications. However, we should
have considered reproducible error at every irradiation
in mobile sites such as the buccal mucosa and lip. Thus,
we had to add a set-up margin of about 5 mm to our
PTV to prevent tumor recurrence in the margins; in
contrast, this approach was not necessary for the gingiva
and hard palate, which are static sites. Thus, the PTV
for the tumors located in the buccal mucosa and lip
Table 2 HDR brachytherapy using mold technique for oral cavity cancers
Author (year) Ref Age Sex Site EBRT HDR brachytherapy Status (months)
Ariji (1999) 7 64 M FM 22 Gy/11 fr 30 Gy/10 fr/5 days BID NED (26)
64 M BM 26 Gy/13 fr 35 Gy/10 fr/5 days BID NED (16)
59 M FM 30 Gy/15 fr 30 Gy/10 fr/5 days BID NED (18)
48 M LG 40 Gy/20 fr 25 Gy/10 fr/5 days BID NED (14)
Cengiz (1999) 8 70 F UG - 40 Gy/10 fr/5 days BID NED (6)
86 F UG - 40 Gy/10 fr/5 days BID DOC (6)
Obinata (2007) 9 73 M LG 60 Gy/24 fr 12 Gy/2 fr/2 days Local Failur (3.5)
76 M UG 30 Gy/12 fr 30 Gy/5 fr/3 days NED (18)
Garrán (2008) 10 64 F UG 46 Gy/ 23fr 32 Gy/8 fr/4 days BID Local Failur (7)
Kudoh (2010) 11 80 F UG 60 Gy/30 fr 50 Gy/10 fr/5 days BID NED (2)
79 F UG 60 Gy/30 fr 30 Gy/10 fr/5 days BID NED (8)
Ref: reference, UG; upper gingiva, FM: floor of mouth, BM: buccal mucosa, LG: lower gingiva.
BID: twice a day, NED: no evidence the disease, DOC: death of cancer.
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(set-up margin).
For HDR brachytherapy using the mold technique, the
American Brachytherapy Society reported that the lips,
buccal mucosa, and hard palate are suitable sites [1].
Some authors have also used this technique to treat
superficial cancers of the gingiva and floor of the mouth
[7-11]. In present study, regarding local recurrence at
the sites of the primary tumors, cases involving the floor
of the mouth (2/2) and the posterior region of the buccal
mucosa (2/3) showed a high recurrence rate. In those
sites, we considered that it may sometimes be difficult to
hold the mold in place because of a patient’s body mo-
tion, caused by factors such as swallowing. If the mold
was detached from the mucosal surface during the ir-
radiation, the radiation dose delivered to the tumor
using HDR brachytherapy might be reduced to a sub-
optimal level as a consequence of a change in the refer-
ence point. We suspected that floor of the mouth and
the posterior region of the buccal mucosa are unsuitable
sites for HDR brachytherapy using the mold technique.
Indeed, when cases involving these sites were excluded,
the 5-year local control rate was improved from 54.1%
(n = 17) to 71.6% (n = 12). Thus, we considered that the
suitable sites for HDR brachytherapy using the mold
technique are the lips, anterior region of the buccal mu-
cosa, hard palate, and gingiva.
For oral cancer, previous studies have adopted HDR
brachytherapy protocols involving a range of total doses,
fraction sizes, and other factors [7-11]. The American
Brachytherapy Society indicated that morbidity in the
oral cavity is associated with a fraction sizes > 6 Gy [1].
In the present study, we administered the prescribed
HDR brachytherapy dose, which was 24 Gy delivered in
four fractions, to all patients on a two fraction per day
basis over a 1-week period. In our protocol, the biologicaleffective dose (BED) delivered to the tumor at the HDR
brachytherapy reference point was 38.4 Gy (32 Gy in 2 Gy
equivalent fractions) according to the linear quadrant
model using an α/β value of 10. In the protocols of 30 Gy
in 5 fractions over 3 weeks and 36 Gy in 6 fractions over
3 weeks, the BED10 of them would be 48 Gy (40 Gy in
2 Gy equivalent fractions) and 57.6 Gy (48 Gy in 2 Gy
equivalent fractions), respectively. On the other hand,
using an α/β value of 3, the BED3 required to induce late
normal tissue damage in these HDR brachytherapy proto-
cols would be 90 Gy (54 Gy in 2 Gy equivalent fractions)
and 108 Gy (about 66 Gy in 2 Gy equivalent fractions), re-
spectively. Considering the BED of our HDR brachyther-
apy scheme, we might be able to increase the total dose of
HDR brachytherapy to 30 Gy delivered in 5 fractions or
36 Gy delivered in 6 fractions to improve local control
rates. However, considering severe late complication such
as osteoradionecrosis, our HDR brachytherapy protocol
involving the delivery of 24 Gy in 4 fractions is suitable for
cancers adjacent to the jawbone, such as those in the gin-
giva or hard palate. On the other hand, we believe that the
risk of osteoradionecrosis in cases involving tumors in the
buccal mucosa and lip which are distant from the jawbone
is lower than is the case for the hard palate and gingiva, al-
though the threshold dose is not clear. Therefore, we
could increase the total dose of HDR brachytherapy for
tumor treatment at these sites.
Conclusions
The outcomes of our study were by no means satisfac-
tory when compared with those of LDR brachytherapy
for lip and oral cavity cancer. Although we need to im-
prove the technical aspects of our protocol, and carefully
consider the indications for treatment, this technique is
a minimally invasive treatment for lip and oral cavity
cancer. Therefore, we consider that it might be an
Unetsubo et al. Radiation Oncology  (2015) 10:81 Page 8 of 8acceptable option for patients with superficial lip or oral
cavity cancer, excluding some sites (floor of the mouth
and posterior region of the buccal mucosa), in patients
who are not eligible for aggressive treatment because of
their age, performance status, or other reasons.
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